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Abstract
Severe sepsis is more and more frequent, especially because of an
increased rate of immunocompromised patients. Despite the
improvement in the overall prognosis of HIV/AIDS patients and the
improvement of global ICU care, the prognosis of HIV/ADS patients
hospitalized in ICU with severe sepsis remained poor. This situation
is partly due to the increased proportion of HIV/AIDS patients with
limited access to health care and to a reluctance of ICU physicians
in admitting HIV infected patients. However, medical literature
suggests that ICU prognosis of immunocompromised (especially
cancer) patients should be largely improved by early ICU admission
and by an early institution of supportive techniques. This strategy
should be used in HIV/AIDS patients with severe sepsis.
In recent years, several papers have noted important
modifications in the epidemiology of sepsis and septic shock
[1,2]. In the USA, the annual incidence of sepsis increased
8.7% [2], with sepsis more frequent among non-white people
and men. Possible reasons for the real increase in the incidence
of sepsis include the increased number of immunocompromised
patients; HIV infected patients represent more than 10% of
patients hospitalized in teaching hospitals with severe sepsis
and 6% of patients hospitalized with septic shock [1].
In industrialized countries, the introduction of highly active
antiretroviral therapy (HAART) has significantly reduced the
morbidity and mortality associated with HIV infection [3,4].
The combination of a stable rate of new HIV cases with the
longer survival of HIV-infected patients has increased the
prevalence of HIV/AIDS [5]. Although the rate of hospital
admissions has decreased in the HIV-infected population, the
proportion of hospitalized patients admitted to intensive care
units (ICUs) did not change [6] or increased [7,8].
Between 1990 and 1996 (the beginning of HAART therapy),
in-ICU mortality [6-9] improved moderately or did not change,
but the three-month [7] and long-term outcome [10] of
HIV/AIDS patients admitted to the ICU improved dramatically.
For example, in the Claude-Bernard Bichat experience, in-ICU
mortality was 20.6% in 1990 to 1992, 27% in 1995 to 1996
and 25% in 1998 to 2000 [7,9]. In contrast, six-month
mortality was 49% in 1990 to 1992, 38% in 1995 to 1996
and 30% in 1998 to 2000 [9,10]. Similar results were found
in Switzerland [11] and the USA [6].
The unmodified ICU prognosis is obviously not related to the
absence of improvements in ICU care, but is largely due to
modifications in the case-mix and attitudes toward the use of
ICU care [12]. Compared to the pre-HAART period, two distinct
categories of HIV/AIDS patients are now admitted. The most
common of these is a particular subgroup of patients with
problems in HIV screening, access to healthcare and
compliance with the treatment. These patients are more
frequently women, intravenous drug abusers, or foreigners with
undiagnosed HIV infection at ICU admission and are more likely
to be admitted through the emergency room [7]. The second
and less common group comprises patients with a known HIV
infection who are admitted with frequent non-AIDS associated
admission diagnoses [6,8,10], such as cardiac (myocardial
infarction) and gastro-intestinal (bleeding, cirrhosis) disorders,
and drug overdose as well as complications of HAART therapy.
In this issue of Critical Care, Mrus et al. [13] studied the
epidemiology and cost of severe sepsis in HIV infected
patients. In a very large cohort of patients hospitalized in six
US states in 1999, they found that patients with HIV/AIDS
had a greater mortality and a lower rate of ICU admission
compared to other patients with severe sepsis.
The major limitation of the study is the use of administrative
data to define severe sepsis. The method used has been
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validated without using individual data and its accuracy could
be largely questioned [14]. The use of ICD-9 codes to
diagnose infection and organ dysfunction is not sufficiently
accurate. Moreover, although the definitions of severe sepsis
combined infection with organ dysfunction within the same
admission, a causal link between organ dysfunction and
infection could only be speculated at as no time frames
between infection and organ dysfunction were defined.
Furthermore, confounding factors could have biased the final
results. In the Mrus et al. study [13], admission for surgery
was less frequent in the HIV/AIDS patients. Admission for
surgery has also been associated with reduced ICU
admission refusal [15]. Admission for surgery could,
therefore, act as a confounder in the relationship between
ICU non-admission and HIV/AIDS status. Similarly, admission
type has been associated with hospital mortality of ICU
patients [16] (scheduled surgery has a better hospital
prognosis than patients admitted for a medical problem or
after an emergency surgery), but was not taken into account
in estimating the relationship between HIV/AIDS status and
hospital mortality.
The study was based on a very large database, however, and,
if its findings are confirmed, suggests that ICU admission of
HIV/AIDS patients is delayed or not accepted and is
associated with a poorer prognosis. This would raise
important questions about triage policies and/or access to
care for HIV-infected patients, even after the dramatic
improvement in the prognosis of HIV disease resulting from
HAART therapy.
For a patient to be admitted to the ICU, where they should
benefit from aggressive therapy, they must be referred to and
then accepted by the ICU team. The preferred use of
palliative care in HIV infected patients seems unlikely,
however, except in cases of HAART failure and multiresistant
viruses, and ICU physicians might still be reluctant to admit
HIV infected patients to the ICU. ICU prognosis of
immunocompromised, especially cancer patients, improves,
however, if patients are admitted early and if supportive
techniques such as non-invasive ventilation are begun quickly
[17]. As access to care becomes more and more difficult for
HIV-AIDS patients, referrals for ICU admission might be
delayed, which would subsequently explain the absence of
improvement in the ICU outcome.
The outcome for septic HIV/AIDS patients should, therefore,
be improved in two different ways: the screening of HIV
infection in populations who find access to care difficult
should be facilitated; and ICU admission of non-palliative care
patients should be encompassing and should not be delayed.
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